Skoči na glavni sadržaj

Izvorni znanstveni članak

Treatment outcomes of patients with BRCA-mutated, recurrent ovarian cancer in University Hospital Center Split

Branka Petrić-Miše ; Department of Oncology, University Hospital Split, Split, Croatia
Mirko Pešo ; School of Medicine, University of Split, Split, Croatia;
Darijo Hrepić ; Department of Medical Psysics, University Hospital Split, Split, Croatia
Vesna Telesmanić-Dobrić ; Department of Oncology, General Hospital Zadar, Zadar, Croatia
Eduard Vrdoljak ; Department of Oncology, University Hospital Split, Split, Croatia

Puni tekst: engleski pdf 605 Kb

str. 16-26

preuzimanja: 124



Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with platinum-sensitive, BRCA-mutated, recurrent ovarian cancer treated at the University Hospital Center Split in the period from June 2016 to April 2021.
Methods: Data were collected retrospectively from a medical history of 28 patients with platinum-sensitive, BRCAmutated, recurrent ovarian cancer. Medical records were reviewed for clinico-pathological characteristics, number of previous chemotherapy lines and platinum-free interval before olaparib, response to olaparib, survival outcomes (time to disease progression, time from first cycle of olaparib to the first cycle of chemotherapy for the first and second relapse / progression, overall survival) and safety. Median follow up time was 27 months.
Results: All patients were BRCA mutated, with a 75% predominance of BRCA1 mutation. The median platinum-free interval was 13 months. Most patients were treated after the first relapse (64%) with a three weekly TC protocol (68%). Olaparib maintenance therapy provided clinical control rate in 43% of cases. The median progression free survival was 24 months. Discontinuation of olaparib treatment was reported due to disease progression in 16 patients. The median time to first subsequent chemotherapy was 31 months and time to second subsequent chemotherapy was 38 months. The tolerability of olaparib was good and the side effects were low intensity. The median overall survival is not reached.
Conclusion: This retrospective analysis of patients with platinum-sensitive, BRCA-mutated, recurrent ovarian cancer showed that the treatment outcomes, ie efficacy and tolerability of olaparib after platinum based chemotherapy in everyday clinical practice, are comparable to those observed in clinical trials with olaparib in the same indications.

Ključne riječi

ovarian cancer recurrence, BRCA mutation, olaparib, treatment outcomes

Hrčak ID:



Podaci na drugim jezicima: hrvatski

Posjeta: 356 *